Olema Pharmaceuticals Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Olema Pharmaceuticals şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-5.0%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-5.0%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Aug 29

Olema Pharmaceuticals: Still Merits A Small Holding

Jun 17

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

May 11

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Mar 28

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Nov 09

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 13

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Aug 09

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Jul 21

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

May 29

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 08

Our Take On Olema Pharmaceuticals

Jan 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 19

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Jun 04

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 19

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: OLMA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: OLMA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Olema Pharmaceuticals Piyasaya Karşı Temettü Getirisi

OLMA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (OLMA)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (OLMA) (3 yıla kadar)	0%

Önemli Temettü: OLMA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, OLMA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: OLMA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: OLMA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Olema Pharmaceuticals Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Chief Operating & Financial Officer exercised options to buy US$207k worth of stock.

New major risk - Revenue and earnings growth

Olema Oncology Announces New Preclinical Combination Data to Be Presented At the 2024 Eortc-Nci-Aacr Symposium on Molecular Targets and Cancer Therapeutics

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

New major risk - Revenue and earnings growth

Director notifies of intention to sell stock

Olema Pharmaceuticals: Still Merits A Small Holding

Director notifies of intention to sell stock

Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Director notifies of intention to sell stock

Insufficient new directors

Olema Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Director notifies of intention to sell stock

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Director notifies of intention to sell stock

Chief Medical Officer exercised options to buy US$241k worth of stock.

Chief Operating & Financial Officer exercised options to buy US$563k worth of stock.

Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies

President recently sold US$824k worth of stock

President notifies of intention to sell stock

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Director notifies of intention to sell stock

Price target increased by 13% to US$24.43

Olema Pharmaceuticals, Inc. Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant

Olema Pharmaceuticals, Inc. Appoints Scott Garland to Its Board of Directors

Olema Pharmaceuticals, Inc. Announces Phase 2 Monotherapy Clinical Results to Be Presented At the 2023 Esmo Congress

Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Olema Pharmaceuticals, Inc. announced that it has received $129.999989 million in funding

Olema Pharmaceuticals, Inc. announced that it expects to receive $129.999989 million in funding

Olema Pharmaceuticals, Inc. announced that it expects to receive $129.999989 million in funding

Director notifies of intention to sell stock

Director notifies of intention to sell stock

Corporate Secretary notifies of intention to sell stock

Corporate Secretary notifies of intention to sell stock

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Director recently sold US$63k worth of stock

Corporate Secretary notifies of intention to sell stock

Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1B/2 Study

Price target increased by 12% to US$15.00

Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Olema Pharmaceuticals, Inc. Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study

Price target decreased to US$14.50

High number of new and inexperienced directors

Olema Pharmaceuticals, Inc. Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial

Olema Oncology grants stock options for 58.3K shares

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) dropped from Russell 2000 Growth Index

Olema Pharmaceuticals, Inc. Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program

Price target decreased to US$26.20

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

Price target decreased to US$30.75

High number of new and inexperienced directors

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Olema Pharmaceuticals, Inc. Announces Management Changes

Our Take On Olema Pharmaceuticals

Chief Development Officer recently sold US$103k worth of stock

Price target decreased to US$46.25

Olema Pharmaceuticals, Inc. Announces First Clinical Data on OP-1250 in Advanced ER+ / HER2- Breast Cancer

Chief Business Officer exercised options and sold US$307k worth of stock

Chief Business Officer exercised options and sold US$136k worth of stock

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

President exercised options and sold US$77k worth of stock

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

New 90-day low: US$36.41